Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy

Aziz, Hafsa; Raza, Abida; Ali, Khawar; Khattak, Jabar Zaman Khan; Irfan, Javaid; Gill, Muzaffar Lateef

doi:10.1016/j.ijid.2014.09.021

Cited by 30 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The IL28B gene encodes cytokine type III IFN, which serves as a natural barrier to a viral infection. The human body is capable of producing cytokines differently depending on the polymorphism of the cytokine production genes [27]. However, the dynamic interactions between genes or between genes and the existing environment affect cytokine production and thus the immune response [28].…”

Section: Discussionmentioning

confidence: 99%

Genetic predictors of the response to the treatment of hepatitis C virus infection

Dzekova‐Vidimliski¹,

Nikolov²,

Matevska-Geshkovska

et al. 2015

Biomol Biomed

View full text Add to dashboard Cite

The genome-wide association studies have identified a strong association between interleukin 28B (IL28B) gene polymorphisms and the response to treatment in patients with hepatitis C virus (HCV) infection. The aim of the study was to evaluate the association between three most widely studied IL28B gene polymorphisms and the response to antiviral treatment of chronic hepatitis C. We performed the genotyping of the three IL28B gene polymorphisms: rs12979860, rs8099917, and rs12980275 in 72 Caucasian patients with chronic hepatitis C, previously treated with the combination therapy of pegylated interferon alpha (PEGIFN α) and ribavirin (RBV). The patients included in the study had finished the treatment regimen at least 6 months before enrolling in the study. We used the sustained viral response (SVR) for the evaluation of the effectiveness of the antiviral treatment, and it was tested with an assay with a sensitivity of 20 IU/mL. An SVR was achieved in 59.7% (43/72) of the treated patients. The three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA genotype of rs12980275) were associated with the SVR (p=0.029, p=0.016, and p=0.028, respectively) in the study patients with chronic hepatitis C treated with the combination therapy of PEGIFN α and RBV. The association of IL28B gene polymorphisms with the treatment response points to the possibility of personalized medicine for the treatment of HCV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic predictors of the response to the treatment of hepatitis C virus infection

Dzekova‐Vidimliski¹,

Nikolov²,

Matevska-Geshkovska

et al. 2015

Biomol Biomed

View full text Add to dashboard Cite

show abstract

“…HCV genotip 2 / genotip 3 ile enfekte 268 kronik HCV hastasında yapılan bir başka çalışmada, IL28B SNP rs12979860 CC genotipi taşıyanların %82'sinde KVC geliştiği ve bu genotipi taşımayanlarla arasında istatistiksel olarak anlamlı bir fark olduğu bildirilmiştir (15) . Pakistan da HCV genotip 3 ile enfekte hastalarda yapılan bir çalışmada, IL28B SNP rs12979860 CC genotipi taşıyanların %84.2'sinde KVC geliştiği gözlenmiştir (16) . HCV genotiplerin bilinmesi enfeksiyonun tedavisinde uygun yaklaşımın belirlenmesi açısından önemli olmaktadır.…”

Section: Gereç Ve Yöntemunclassified

“…Bu çalışmada, Adnan Menderes Üniversitesi Uygulama ve Araştırma Hastanesi'nde takip edilmekte olan kronik HCV hastalarında antiviral tedaviye erken ve kalıcı viral yanıt ile IL-28B (rs12979860) polimorfizmi arasındaki ilişkinin araştırılması amaçlanmıştır. (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) . Bazı çalışmalarda ise, IL28B (rs12979860) genotipi ile KVC gelişimi arasında anlamlı bir ilişki gösterilememiştir (26,27) .…”

Section: Introductionunclassified

The distribution of IL28B polymorphism (rs12979860) and its effect on the response to treatment in patient with chronic hepatitis C virus in Aydın province

Aydın¹,

Bülbül²,

Çoşkun³

et al. 2018

TMCD

View full text Add to dashboard Cite

ÖZ Amaç: Hepatit C virus enfeksiyonları yüksek oranda kronikleşmekte ve kronik hepatit C infeksiyonlu hastalar ikili veya üçlü antiviral ilaç kombinasyonu ile tedavi edilmektedir. Ancak kronik HCV enfeksiyonlarının tedavisinde hastaların tedaviye verdiği yanıtı etkileyen birçok faktör tanımlanmıştır. Bunlardan biri, tedavi sonunda oluşan kalıcı virolojik yanıt (KVC) ile IL-28B polimorfizmi arasındaki ilişkidir. Bu çalışmada, antiviral tedavi uygulanan kronik HCV hastalarında IL-28B (rs12979860) polifmorfizmindeki dağılım ve kalıcı virolojik yanıt arasındaki ilişkinin gösterilmesi amaçlanmıştır. Gereç ve Yöntem: Çalışmaya peginterferon-ribavirin tedavisi alan kronik HCV enfeksiyonu olan hastalar alınmıştır. Tedavinin 12. haftasında, tedavi bitiminde ve altı ay sonraki kontrollerde HCV RNA araştırılarak, erken ve kalıcı virolojik yanıt belirlenmiştir. Bulgular: Çalışmaya dâhil edilen 41 hastanın, 18'i (%43.9) erkek, 23'ü (%56.1) kadındır. Hastalarda IL28B SNP varyantı olan rs12979860'in %12.2'si CC genotipi, %19.5'i TT genotipi, %68.3'ü TC genotipi olarak tanımlanmıştır. Erken virolojik yanıt CC genotipi taşıyan hastalarda %80, TT genotipinde %75, TC genotipinde %82.1 olarak bulunmuş ve erken virolojik yanıt açısından IL-28B genotipleri arasında istatistiksel olarak anlamlı bir fark bulunmamıştır. Hastalarda kalıcı virolojik yanıt ise CC genotipi taşıyan hastalarda %100 iken, TT ve TC genotiplerinde sırasıyla % 62.5 ve % 46.4 olarak bulunmuştur. Kalıcı virolojik yanıt CC genotipi bulunan hastalarda diğer genotiplere göre istatistiksel olarak anlamlı olarak yüksek oranda bulunmuştur (p=0.035). Sonuç: Bu sonuçlara göre, IL28B (rs12979860) CC genotipleri taşıyan kronik HCV enfeksiyonlu hastalarda yüksek oranda KVC alınmaktadır. Ancak bölgemizde kronik HCV enfeksiyonlu hastalarda CC genotipleri düşük oranda taşınmakta, KVC'ın daha düşük oranda olduğu diğer genotipler ise yaygın bulunmaktadır. Bu nedenlerden dolayı, bölgemizde kronik HCV enfeksiyonlu hastalarda tedavinin planlanmasında ve takibinde IL28B (rs12979860) CC genotiplerin düşük oranda olduğunun dikkate alınmasının yararlı olacağı düşünülmektedir. Anahtar kelimeler: Kronik HCV enfeksiyonu, IL28B poliformizmi, peginterferon-ribavirin tedavisi ABSTRACT The Distribution of IL28B Polymorphism (rs12979860) and its Effect on the Response to Treatment in Patients with Chronic Hepatitis C Virus in Aydın ProvinceObjective: Hepatitis C virus (HCV) infections have become increasingly chronic and the patients with chronic hepatitis C infections are given dual or triple antiviral drug combinations. However many factors are described affecting the response of the patients to treatment. One of them is the relationship between sustained virological response to treatment and IL-28B polymorphism. In this study, we aimed to investigate the relationship between the distribution of IL-28B (rs12979860) polymorphism. Material and Methods:This study was conducted with chronic HCV patients undergoing peginterferon-ribavirin treatment. HCV RNA was investigated at the 12 th week of the ...

show abstract

“…The HepG2.2.15 cells containing two integrated head-to-tail copies of the genotype D and stably replicating the HBV genome [4] are currently used to evaluate the effect of antiviral compounds [5][6][7]. However, in…”

Section: Introductionmentioning

confidence: 99%

Establishment of stable cell lines in which the HBV genome replicates episomally for evaluation of antivirals

Sun

Liu

et al. 2020

aoms

View full text Add to dashboard Cite

Introduction: Due to the increasing resistance to nucleot(s)ide analogs in patients with chronic hepatitis B, development of new antiviral drugs to eradicate hepatitis B virus is still urgently needed. Material and methods: To date, most studies on evaluating anti-HBV drugs have been performed using cell lines where the HBV genomic DNA is chromosomally integrated, e.g. Hep2.2.15 in HBV-infected livers of the viral episomal genome replicates in the nucleus and covalently closed circular DNA (cccDNA) serves as a transcriptional template. Another option involves the use of HBV-infected cells of HepaRG or NTCP-overexpressing cells. However, the development of the infection system is expensive and laborious, and its HBV expression level remained low. Results: Compared to HuH7 cells, the established stable cell lines based on episomal-type pEB-Multi vectors can been expressed HBV wild-type by qRT-PCR and immunoblotting (p < 0.05). These two vectors are also sensitive to Entecavir and against nucleoside analog Lamivudine in mutants cellines. Conclusions: It is worth demonstrating how useful the established cell system is for evaluating antiviral agents and their mechanisms of action.

show abstract

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy

Abstract: HCV-infected patients carrying homozygous C/C have a higher chance of SVR. In addition, patients who carry T/T (rs8099917) have a higher chance of RVR.

Cited by 30 publications

References 27 publications

Genetic predictors of the response to the treatment of hepatitis C virus infection

Genetic predictors of the response to the treatment of hepatitis C virus infection

The distribution of IL28B polymorphism (rs12979860) and its effect on the response to treatment in patient with chronic hepatitis C virus in Aydın province

Establishment of stable cell lines in which the HBV genome replicates episomally for evaluation of antivirals

Contact Info

Product

Resources

About